(19)
(11) EP 1 755 650 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.10.2008 Bulletin 2008/42

(45) Mention of the grant of the patent:
09.07.2008 Bulletin 2008/28

(21) Application number: 05753131.1

(22) Date of filing: 23.05.2005
(51) International Patent Classification (IPC): 
A61K 38/21(2006.01)
A61K 9/00(2006.01)
 A61K 9/16(2006.01)
A61K 47/18(2006.01)
(86) International application number:
PCT/US2005/017914
(87) International publication number:
WO 2005/115333 (08.12.2005 Gazette 2005/49)

(54)

A BIOMOLECULE-CONTAINING SUSPENSION FORMULATION OF INCREASED STABILITY DELIVERABLE VIA AN IMPLANTABLE DELIVERY DEVICE

EINE BIOMOLEKÜLE ENTHALTENDE SUSPENSIONSFORMULIERUNG VON ERHÖHTER STABILITÄT - FREISETZBAR ÜBER EIN IMPLANTIERBARES HILFSMITTEL

UNE SUSPENSION CONTENANT UNE BIOMOLÉCULE - D'UNE STABILITÉ AUGMENTÉE ET D'UNE ADMINISTRATION PAR UN DISPOSITIF IMPLANTABLE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: 25.05.2004 US 574662 P
03.02.2005 US 650226 P

(43) Date of publication of application:
28.02.2007 Bulletin 2007/09

(73) Proprietor: Intarcia Therapeutics, Inc
Hayward CA 94545 (US)

(72) Inventors:
  • JUNNARKAR, Gunjan
    Palo Alto, California 94303 (US)
  • DESJARDIN, Michael A.
    Sunnyvale, CA 94087 (US)
  • LIU, Kui
    Redwood City, CA 94065 (US)
  • LI, Zengji
    San Ramon, CA 94583 (US)

(74) Representative: Walton, Seán Malcolm et al
Mewburn Ellis LLP York House 23 Kingsway
London WC2B 6HP
London WC2B 6HP (GB)


(56) References cited: : 
WO-A-20/04056338
US-A1- 2003 044 467
US-A1- 2003 215 515
 US-A- 5 219 572
US-A1- 2003 059 376
US-B1- 6 468 961
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).